RE:Lawsuit IMO, this is not the way to have a change in the way Theratechnologies' BoD fullfill its fiduciary duties and communicates with its shareholders.
Theratechnologies needs to be free cash flow positive for a number of consecutive quarters with its legacy drugs AND not burn it all with its useless research.
The R&D department needs to be trimmed down at least 50% and selling expense of 40%+ of sales revenues needs to be reduced substancially to generate enough cash to eliminate debt.
Finally, the Director behind the awfull way they have been communicating should be shown the door by a shareholder vote of no confidence. Underwise, not much will change...